COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Article Collection: COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
https://www.ncbi.nlm.nih.gov/pubmed/32671831
http://dx.doi.org/10.1111/cei.13495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
https://www.ncbi.nlm.nih.gov/pubmed/32671831
http://dx.doi.org/10.1111/cei.13495

Ejemplares similares